SEC Filing Summary: Hemispherx Biopharma, Inc. (10-K)
Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc.
Filing Type: Annual Report (Form 10-K)
Period Ended: December 31, 2009
Business Overview: A specialty pharmaceutical company focused on clinical development of immune system-enhancing therapies for viral and chronic disorders. The company's primary assets are Ampligen (experimental RNA drug for Chronic Fatigue Syndrome and influenza adjuvant) and Alferon N Injection (FDA-approved natural interferon for genital warts, currently not in commercial production).
Key Financial Metrics (Year Ended Dec 31, 2009)
| Metric | 2009 Value | 2008 Value |
|---|---|---|
| Total Revenues | $111,000 | $265,000 |
| Net Loss | $(13,438,000) | $(12,219,000) |
| Loss Per Share (Basic/Diluted) | $(0.12) | $(0.16) |
| Research & Development Expenses | $6,995,000 | $5,800,000 |
| Cash and Cash Equivalents | $58,072,000 | $6,119,000 |
| Working Capital | $55,789,000 | $5,646,000 |
| Accumulated Deficit | $(210,847,000) | $(197,409,000) |
Note: The filing text does not provide specific gross margin percentages due to the lack of commercial product sales in 2009.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped 58% to $111,000. This was driven by the complete cessation of commercial sales of Alferon N Injection (which generated $173,000 in 2008) due to inventory expiration in March 2008. The only 2009 revenue came from the Ampligen cost-recovery clinical program ($111,000).
- Increased R&D Costs: R&D expenses rose 21% to $6.995 million, primarily due to costs associated with responding to the FDA's Complete Response Letter (CRL) for Ampligen, manufacturing facility upgrades, and patent write-offs ($214,000).
- Significant Cash Infusion: Cash and cash equivalents increased by approximately $52 million (from $6.1M to $58.1M) following two equity financings in May 2009 (Rodman & Renshaw) and the completion of a $30M purchase agreement with Fusion Capital.
- Manufacturing Status: Commercial production of Alferon N Injection remains halted. A $4.4 million capital improvement program was approved to upgrade the New Brunswick facility, with commercial sales potentially resuming in mid-to-late 2011.
Guidance, Outlook, and Risks
Regulatory Status (Ampligen)
On November 25, 2009, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for Ampligen to treat Chronic Fatigue Syndrome (CFS). The FDA determined the application could not be approved in its present form. Key requirements include:
- Conducting at least one additional clinical study with convincing efficacy and safety data (minimum 300 patients, 6-month duration).
- Performing rodent carcinogenicity studies in two species.
- Resolving manufacturing inspection issues at the New Brunswick facility and the Hollister-Stier subcontractor site.
The company submitted new preclinical data in January 2010 addressing certain safety concerns and intends to plan a confirmatory clinical study.
Regulatory Status (Alferon LDO)
A proposed Phase 2 clinical study for Alferon LDO (oral interferon for influenza) is currently on Clinical Hold by the FDA. The hold is due to deficiencies in the protocol design and Chemistry, Manufacturing, and Controls (CMC) issues, specifically regarding the stability of drug product manufactured from API stored for approximately nine years. The company expects to submit new stability data in Spring 2010.
Key Risks and Contingencies
- Product Liability: The company suspended product liability insurance for Ampligen and Alferon in November 2008. A claim could have a materially adverse effect on operations.
- Litigation: Multiple securities class action lawsuits and shareholder derivative suits were filed in late 2009/early 2010 alleging misrepresentation regarding the status of the Ampligen NDA. Additionally, the company is defending against claims from MidSouth Capital and Cato Capital regarding placement fees.
- Financing Needs: Despite the recent cash infusion, the company may require additional financing to complete clinical trials and regulatory processes. The ability to raise equity is limited by the number of authorized shares (200 million), as a proposal to increase this to 350 million failed in 2009.
- Manufacturing Delays: Resumption of Alferon N Injection sales is contingent on successful facility upgrades and FDA lot approvals, with a target of mid-to-late 2011.
Investor Verification Checklist
- Ampligen Clinical Study Design: Verify the timeline and design of the new confirmatory clinical study required by the FDA to address the CRL.
- Alferon LDO Clinical Hold: Monitor the submission and FDA acceptance of new stability data for the Alferon LDO clinical trial in Spring 2010.
- Manufacturing Upgrades: Confirm progress on the $4.4 million capital improvement program at the New Brunswick facility and resolution of FDA Form 483 inspection issues.
- Litigation Exposure: Review the status of the consolidated securities class action lawsuits and the MidSouth/Cato Capital disputes for potential financial impact.
- Capital Structure: Assess the impact of the failed vote to increase authorized shares on future fundraising capabilities and potential dilution from outstanding warrants.